comparemela.com

Med Econ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Clinical use of pre-emptive pharmacogenetic programmes

The clinical implementation of pharmacogenetics (the study of how genetics influence individual variations in drug response) is a key factor in the development of programmes to prevent adverse drug reactions. Yet pharmacogenetics testing in clinics is still infrequent and is mainly reactive and focused on analysing a single drug–gene interaction. Evaluation of the implementation of pharmacogenetics in the real world is necessary. Only very few pilot studies have used a pharmacogenetics panel strategy to guide drug therapy, and mostly in patients aged over 65 years in specialised care settings in the USA.

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

These updated, long-term data from CROWN show the durable benefit of lorlatinib over crizotinib in patients with treatment-naive, ALK-positive non-small-cell lung cancer and support the use of first-line lorlatinib in patients with and without baseline brain metastases.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.